Brain gene therapy hopes to restore dopamine in young Parkinson's patients
NCT ID NCT07267065
First seen Dec 12, 2025 · Last updated May 22, 2026 · Updated 20 times
Summary
This early-stage study tests a gene therapy called AAV2-hAADC in 9 adults aged 18-75 with young onset Parkinson's (symptoms before age 50). The therapy delivers a gene into brain areas that help turn levodopa into dopamine, the chemical missing in Parkinson's. The main goal is to check safety, but researchers will also look for signs of improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ohio State University
Columbus, Ohio, 43210, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.